Mycophenolate Mofetil Attenuates DOCA-Salt Hypertension: Effects on Vascular Tone

被引:13
|
作者
Moes, Arthur D. [1 ]
Severs, David [1 ]
Verdonk, Koen [2 ]
van der Lubbe, Nils [1 ]
Zietse, Robert [1 ]
Danser, A. H. J. [2 ]
Hoorn, Ewout J. [1 ]
机构
[1] Erasmus Univ, Erasmus Med Ctr, Dept Internal Med, Div Nephrol & Transplantat, Rotterdam, Netherlands
[2] Erasmus Univ, Erasmus Med Ctr, Dept Internal Med, Div Pharmacol & Vasc Med, Rotterdam, Netherlands
来源
FRONTIERS IN PHYSIOLOGY | 2018年 / 9卷
关键词
angiotensin II; endothelin-1; salt-sensitive hypertension; sodium transporters; wire myographs; II TYPE-2 RECEPTOR; SODIUM-CHLORIDE COTRANSPORTER; IMMUNE CELL INFILTRATION; NA-CL COTRANSPORTER; ANGIOTENSIN-II; BLOOD-PRESSURE; SENSITIVE HYPERTENSION; MEDIATED VASODILATION; ACTIVATION; VASOCONSTRICTION;
D O I
10.3389/fphys.2018.00578
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Inflammation is increasingly recognized as a driver of hypertension. Both genetic and pharmacological inhibition of B and T cells attenuates most forms of experimental hypertension. Accordingly, the immunosuppressive drug mycophenolate mofetil (MMF) reduces blood pressure in the deoxycorticosterone acetate (DOCA-) salt model. However, the mechanisms by which MMF prevent hypertension in the DOCA-salt model remain unclear. Recent studies indicate that immunosuppression can inhibit sodium transporter activity in the kidney, but its effect on vascular tone is not well characterized. Therefore, the aim of the present study was to analyze the vascular and renal tubular effects of MMF in the DOCA-salt model in rats (4 weeks without uninephrectomy). Co-treatment with MMF attenuated the rise in blood pressure from day 11 onward resulting in a significantly lower telemetric mean arterial pressure after 4 weeks of treatment (108 +/- 7 vs. 130 +/- 9 mmHg, P < 0.001 by two-way analysis of variance). MMF significantly reduced the number of CD3(+) cells in kidney cortex and inner medulla, but not in outer medulla. In addition, MMF significantly reduced urinary interferon-gamma excretion. Vascular tone was studied ex vivo using wire myographs. An angiotensin II type 2 {AT(2)) receptor antagonist blocked the effects of angiotensin II (Ang II) only in the vehicle group. Conversely, L-NAME significantly increased the Mg II response only in the MMF group. An endothelin A receptor blocker prevented vasoconstriction by endothelin-1 in the MMF but not in the vehicle group. MMF did not reduce the abundances of the kidney sodium transporters NHE3, NKCC2, NCC, or ENaC. Together, our ex vivo results suggest that DOCA-salt induces AT(2) receptor-mediated vasoconstriction. MMF prevents this response and increases nitric oxide availability. These data provide insight in the antihypertensive mechanism of MMF and the role of inflammation in dysregulating vascular tone.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] No evidence for brain renin-angiotensin system activation during DOCA-salt hypertension
    Uijl, Estrellita
    Ren, Liwei
    Colafella, Katrina M. Mirabito
    van Veghel, Richard
    Garrelds, Ingrid M.
    Domenig, Oliver
    Poglitsch, Marko
    Zlatev, Ivan
    Kim, Jae B.
    Huang, Stephen
    Melton, Lauren
    Hoorn, Ewout J.
    Foster, Don
    Danser, A. H. Jan
    CLINICAL SCIENCE, 2021, 135 (02) : 259 - 274
  • [32] TGR5 attenuates DOCA-salt hypertension through regulating histone H3K4 methylation of ENaC in the kidney
    Xu, Long
    Wu, Xinyan
    Long, Luosha
    Li, Suchun
    Huang, Meiying
    Li, Meng
    Feng, Pinning
    Levi, Moshe
    Chen, Wei
    Wang, Lei
    Li, Chunling
    Wang, Weidong
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2025, 165
  • [33] IL-1R Mediated Activation of Renal Sensory Nerves in DOCA-Salt Hypertension
    Baumann, Daniel
    Van Helden, Dusty
    Evans, Louise C.
    Vulchanova, Lucy
    Dayton, Alex
    Osborn, John W.
    HYPERTENSION, 2024, 81 (08) : 1811 - 1821
  • [34] Evidence of Cardiovascular Calcification and Fibrosis in Pseudoxanthoma Elasticum Mouse Models Subjected to DOCA-Salt Hypertension
    Omarjee, Loukman
    Roy, Charlotte
    Leboeuf, Christophe
    Favre, Julie
    Henrion, Daniel
    Mahe, Guillaume
    Leftheriotis, Georges
    Martin, Ludovic
    Janin, Anne
    Kauffenstein, Gilles
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [35] Evaluation of Renal Oxidative Stress in the Development of DOCA-Salt Induced Hypertension and Its Renal Damage
    Seifi, Behjat
    Kadkhodaee, Mehri
    Karimian, Seyed M.
    Zahmatkesh, Maryam
    Xu, Jie
    Soleimani, Manoocher
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2010, 32 (02) : 90 - 97
  • [36] Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats
    Viel, Emilie C.
    Benkirane, Karim
    Javeshghani, Danesh
    Touyz, Rhian M.
    Schiffrin, Ernesto L.
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2008, 295 (01): : H281 - H288
  • [37] Contribution of central nitric oxide to the regulation of blood pressure and sodium balance in DOCA-salt hypertension
    Seto, Shinji
    Nagao, Shoichi
    Ozeki, Shin-ichiro
    Tetsuo, Hirokuni
    Akahoshi, Masazumi
    Yano, Katsusuke
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2006, 47 (05) : 680 - 685
  • [38] Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCA-salt hypertension
    Gomez-Guzman, Manuel
    Jimenez, Rosario
    Sanchez, Manuel
    Jose Zarzuelo, Maria
    Galindo, Pilar
    Maria Quintela, Ana
    Lopez-Sepulveda, Rocio
    Romero, Miguel
    Tamargo, Juan
    Vargas, Felix
    Perez-Vizcaino, Francisco
    Duarte, Juan
    FREE RADICAL BIOLOGY AND MEDICINE, 2012, 52 (01) : 70 - 79
  • [39] Endothelin-1 secretion from cultured vascular endothelial cells of DOCA-salt hypertensive rats
    Takada, K
    Matsumura, Y
    Dohmen, S
    Mitsutomi, N
    Takaoka, M
    Morimoto, S
    LIFE SCIENCES, 1996, 59 (09) : PL111 - PL116
  • [40] Hydrochlorothiazide Reduces Cardiac Hypertrophy, Fibrosis and Rho-Kinase Activation in DOCA-Salt Induced Hypertension
    Mondaca-Ruff, David
    Araos, Patricio
    Yanez, Cristian E.
    Novoa, Ulises F.
    Mora, Italo G.
    Ocaranza, Maria Paz
    Jalil, Jorge E.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2021, 26 (06) : 724 - 735